BLAINVILLE, QC, Sept. 13, 2016 /CNW Telbec/ - Duchesnay Inc. proudly announced today that it has entered into a license and supply agreement with Medinova AG, a Swiss pharmaceutical company. The agreement grants Duchesnay exclusive Canadian rights to market FLUOMIZIN™, a product indicated for the treatment of vaginal infections.
FLUOMIZIN™ is a vaginal tablet containing dequalinium chloride, a well-established anti-infection and antiseptic quinolone derivative used in the treatment of certain vaginal infections. Currently, there are no approved products in Canada containing dequalinium chloride for vaginal use. Duchesnay plans to submit a New Drug Application to Health Canada and will consult with the agency to ensure that all requirements are met prior to filing.
"Duchesnay is pleased to add FLUOMIZIN™ to its growing portfolio of women's health products. If approved, FLUOMIZIN™ has the potential to contribute to improving the health and quality of life of women who suffer from vaginal infections. This agreement with Medinova AG reinforces Duchesnay's position as a Canadian leader in women's health," explained Éric Gervais, Executive Vice President of Duchesnay.
"We are delighted to partner with Duchesnay to introduce FLUOMIZIN™ in Canada. FLUOMIZIN™ has been studied in extensive clinical trials and has already been approved in 39 countries across Europe, Asia-Pacific, the Middle East, Africa and Central America. We are much looking forward to adding Canada to the list of countries where Medinova's products will be present." says Frank Buennig, Managing Director of Medinova AG.
Duchesnay Inc. is a Canadian specialty pharmaceutical company dedicated to improving the health and quality of life of pregnant women by working to advance maternal-foetal medicine to reduce the risks of birth defects and by developing safe and effective pharmacological solutions for use during pregnancy and breastfeeding.
Duchesnay's commitment to women's health does not stop at pregnancy and breastfeeding. Duchesnay is equally committed to ensuring women's health and improving their quality of life at every stage. Thus, Duchesnay offers a continuously expanding portfolio of high-quality, effective treatment options in both obstetrics and gynecology. For more information about the company, visit http://www.duchesnay.com/en/.
Medinova AG was founded in 1945 as a pharmacy in Zurich, Switzerland, by Dr. Fritz Müller. Over the following decades, Medinova quickly grew its operations and production facilities, manufacturing pharmaceutical specialty products for pharmacists and synthesizing chemical raw materials for several foreign markets.
Today, Medinova markets and distributes prescription drugs and over-the-counter products in gynecology, dermatology, rheumatology and other therapeutic areas in over 45 countries worldwide. The company actively manages its core products throughout their life cycle and remains committed to maintaining the highest quality standards and achieving continuous growth through its broad network of partners. For more information, visit http://www.medinova.ch/en/.
SOURCE Duchesnay inc.
Image with caption: "Logo: Duchesnay Inc. (CNW Group/Duchesnay inc.)". Image available at: http://photos.newswire.ca/images/download/20160913_C1244_PHOTO_EN_771248.jpg
For further information: DUCHESNAY: Ron Vaillancourt, Communications Manager, Duchesnay, 1 877 833-7734 firstname.lastname@example.org; Alida Alepian, Principal Advisor, Capital-Image, (514) 739-1188, extension 239, aalepian@capital-Image.com